Patents by Inventor Stephen J. Hoffman

Stephen J. Hoffman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6894185
    Abstract: A family of substituted chiral allosteric effectors of hemoglobin is useful for delivering more oxygen to hypoxic and ischemic tissues by reducing the oxygen affinity of hemoglobin in whole blood.
    Type: Grant
    Filed: September 10, 2002
    Date of Patent: May 17, 2005
    Assignee: Allós Therapeutics, Inc.
    Inventors: Donald J. Abraham, Gajanan S. Joshi, Stephen J. Hoffman, Melissa Grella, Richmond Danso-Danquah, Amal Yousseff, Martin Safo, Sanjeev Kulkarni
  • Patent number: 6828125
    Abstract: The alpha subunits of hemoglobin, which in nature are formed as separate polypeptide chains which bind noncovalently to the beta subunits, are here provided in the form of the novel molecule di-alpha globin, a single polypeptide chain defined by connecting the two alpha subunits either directly via peptide bond or indirectly by a flexible amino acid or peptide linker. Di-alpha globin may be combined in vivo or in vitro with beta globin and heme to form hemoglobin. Di-alpha globin is expressed by recombinant DNA techniques. Di-beta globin may be similarly obtained.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: December 7, 2004
    Assignee: Baxter Biotech Technology, S.a.r.l.
    Inventors: Stephen J. Hoffman, Douglas L. Looker, Kiyoshi Nagai
  • Publication number: 20030130523
    Abstract: A family of substituted chiral allosteric effectors of hemoglobin is useful for delivering more oxygen to hypoxic and ischemic tissues by reducing the oxygen affinity of hemoglobin in whole blood.
    Type: Application
    Filed: September 10, 2002
    Publication date: July 10, 2003
    Inventors: Donald J. Abraham, Gajanan S. Joshi, Stephen J. Hoffman, Melissa Grella, Richmond Danso-Danquah, Amal Yousseff, Martin Safo, Sanjeev Kulkarni
  • Patent number: 6534501
    Abstract: Chemical structures have been identified which allosterically modify pyrvate kinase and inhibit enzymatic activity. These compounds can be used as pharmaceuticals in the treatment of a wide variety of diseases and disorders where influencing metabolic processes is beneficial, such as the glycolytic pathway, all pathways which use ATP as an energy source, and all pathways which involve 2,3-diphosphoglycerate related to the delivery of oxygen by modifying hemoglobin's oxygen affinity, treatments of tumor and cancer and Alzheimer's disease (AD).
    Type: Grant
    Filed: March 7, 2001
    Date of Patent: March 18, 2003
    Assignees: Allos Therapeutics, Inc., Virginia Commonwealth University
    Inventors: Donald J. Abraham, Changging Wang, Richmond Danso-Danquah, James C. Burnett, Gajanan S. Joshi, Stephen J. Hoffman
  • Patent number: 6486342
    Abstract: A family of substituted chiral allosteric effectors of hemoglobin is useful for delivering more oxygen to hypoxic and ischemic tissues by reducing the oxygen affinity of hemoglobin in whole blood.
    Type: Grant
    Filed: August 23, 2000
    Date of Patent: November 26, 2002
    Assignee: Virginia Commonwealth University
    Inventors: Donald J. Abraham, Gajanan S. Joshi, Stephen J. Hoffman, Melissa Grella, Richmond Danso-Danquah, Amal Yousseff, Martin Safo, Sanjeev Kulkarni
  • Publication number: 20020025791
    Abstract: A preferred embodiment of the present invention generally comprises a hand-held two-way radio employing digital selective calling. The hand-held two-way radio further comprises a VCO operative to modulate the radio signal frequencies of a guard channel such that the guard channel can be changed by changing the output of the VCO. In addition, the present invention comprises a hand-held two-way radio comprising circuitry operative to function according to the digital selective calling international standards, and a VCO operative to modulate the radio signal frequencies of a guard channel such that the guard channel can be changed by changing the output of the VCO. A fourth embodiment of the present invention comprises a hand-held two-way radio comprising circuitry operative to send and receive GPS data, and a VCO operative to modulate the radio signal frequencies of a guard channel such that the guard channel can be changed by changing the output of the VCO.
    Type: Application
    Filed: March 20, 2001
    Publication date: February 28, 2002
    Inventors: John W. Englert, Stephen J. Hoffman
  • Patent number: 6214879
    Abstract: Chemical structures have been identified which allosterically modify pyrvate kinase and either inhibit or activate enzymatic activity. These compounds can be used as pharmaceuticals in the treatment of a wide variety of diseases and disorders where influencing metabolic processes is beneficial, such as the glycolytic pathway, all pathways which use ATP as an energy source, and all pathways which involve 2,3-diphosphoglycerate.
    Type: Grant
    Filed: March 24, 1998
    Date of Patent: April 10, 2001
    Assignee: Virginia Commonwealth University
    Inventors: Donald J. Abraham, Richmond E. Danso-Danquah, Telih Boyiri, Changquing Wang, Michael J. Gerber, Stephen J. Hoffman, Gajanan Joshi
  • Patent number: 6124114
    Abstract: Cysteine substitution mutants of alpha and/or beta globin mutants are produced by recombinant DNA techniques and used in the construction, intracellularly or otherwise, of mutant hemoglobins in which alpha- and beta-globin like subunits are crosslinked by disulfide bonds. Solutions of these mutant hemoglobins are used as blood substitutes.Preferably, these mutant hemoglobins contain further mutations which reduce their affinity for oxygen.Hemoglobins are preferably obtained by recombinant DNA techniques. Both alpha and beta globin chains can now be readily expressed, making possible the commercial production of wholly artificial hemoglobin, whether conventional or mutant in form. Solutions of wholly artificial hemoglobins are also used as blood substitutes. Expression of the alpha glolbin gene was substantially improved by means of a beta globin gene "header".
    Type: Grant
    Filed: May 26, 1995
    Date of Patent: September 26, 2000
    Assignee: Baxter Biotech Technology Sarl
    Inventors: Stephen J. Hoffman, Kiyoshi Nagai
  • Patent number: 5844088
    Abstract: The alpha subunits of hemoglobin, which in nature are formed as separate polypeptide chains which bind noncovalently to the beta subunits, are here provided in the form of the novel molecule di-alpha globin, a single polypeptide chain defined by connecting the two alpha subunits either directly via peptide bond or indirectly by a flexible amino acid or peptide linker. Di-alpha globin may be combined in vivo or in vitro with beta globin and heme to form hemoglobin. Di-alpha globin is expressed by recombinant DNA techniques. Di-beta globin may be similarly obtained.We further describe the production of tetrameric human hemoglobin and di-alpha/beta.sub.2 hemoglobin in the yeast Saccharomyces cerevisiae. The synthesis of the protein is directed by a synthetic promotor consisting of two functional parts, an upstream activator sequence (UAS) that confers inducible transcription by galactose from a consensus yeast transcriptional initiation site.
    Type: Grant
    Filed: May 19, 1995
    Date of Patent: December 1, 1998
    Assignee: Somatogen, Inc.
    Inventors: Stephen J. Hoffman, Douglas L. Looker, Mary S. Rosendahl, Gary L. Stetler, Michael Wagenbach, David C. Anderson, Antony James Mathews, Kiyoshi Nagai
  • Patent number: 5844089
    Abstract: The alpha subunits of hemoglobin, which in nature are formed as separate polypeptide chains which bind noncovalently to the beta subunits, are here provided in the form of the novel molecule di-alpha globin, a single polypeptide chain defined by connecting the two alpha subunits either directly via peptide bond or indirectly by a flexible amino acid or peptide linker. Di-alpha globin may be combined in vivo or in vitro with beta globin and heme to form hemoglobin. Di-alpha globin is expressed by recombinant DNA techniques. Di-beta globin may be similarly obtained.
    Type: Grant
    Filed: May 25, 1995
    Date of Patent: December 1, 1998
    Assignee: Somatogen, Inc.
    Inventors: Stephen J. Hoffman, Douglas L. Looker, Mary S. Rosendahl, Gary L. Stetler, Michael Wagenbach, David C. Anderson, Antony James Mathews, Kiyoshi Nagai
  • Patent number: 5798227
    Abstract: The alpha subunits of hemoglobin, which in nature are formed as separate polypeptide chains which bind noncovalently to the beta subunits, are here provided in the form of the novel molecule di-alpha globin, a single polypeptide chain defined by connecting the two alpha subunits either directly via peptide bond or indirectly by a flexible amino acid or peptide linker. Di-alpha globin may be combined in vivo or in vitro with beta globin and heme to form hemoglobin. Di-alpha globin is expressed by recombinant DNA techniques. Di-beta globin may be similarly obtained.We further describe the production of tetrameric human hemoglobin and di-alpha/beta.sub.2 hemoglobin in the yeast Saccharomyces cerevisiae. The synthesis of the protein is directed by a synthetic promotor consisting of two functional parts, an upstream activator sequence (UAS) that confers inducible transcription by galactose from a consensus yeast transcriptional initiation site.
    Type: Grant
    Filed: May 19, 1995
    Date of Patent: August 25, 1998
    Assignee: Somatogen, Inc.
    Inventors: Stephen J. Hoffman, Douglas L. Looker, Gary L. Stetler, Michael Wagenbach
  • Patent number: 5776890
    Abstract: Cysteine substitution mutants of alpha and/or beta globin mutants are produced by recombinant DNA techniques and used in the construction, intracellularly or otherwise, of mutant hemoglobins in which alpha- and beta-globin like subunits are crosslinked by disulfide bonds. Solutions of these mutant hemoglobins are used as blood substitutes. Preferably, these mutant hemoglobins contain further mutations which reduce their affinity for oxygen. Hemoglobins are preferably obtained by recombinant DNA techniques. Both alpha and beta globin chains can now be readily expressed, making possible the commercial production of wholly artificial hemoglobin, whether conventional or mutant in form. Solutions of wholly artificial hemoglobins are also used as blood substitutes. Expression of the alpha globin gene was substantially improved by means of a beta globin gene "header".
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: July 7, 1998
    Assignee: Somatogen, Inc.
    Inventors: Stephen J. Hoffman, Kiyoshi Nagai
  • Patent number: 5744329
    Abstract: The alpha subunits of hemoglobin, which in nature are formed as separate polypeptide chains which bind noncovalently to the beta subunits, are here provided in the form of the novel molecule di-alpha globin, a single polypeptide chain defined by connecting the two alpha subunits either directly via peptide bond or indirectly by a flexible amino acid or peptide linker. Di-alpha globin may be combined in vivo or in vitro with beta globin and heme to form hemoglobin. Di-alpha globin is expressed by recombinant DNA techniques. Di-beta globin may be similarly obtained.
    Type: Grant
    Filed: May 19, 1995
    Date of Patent: April 28, 1998
    Assignee: Somatogen, Inc.
    Inventors: Stephen J. Hoffman, Douglas L. Looker, Mary S. Rosendahl, Gary L. Stetler, Michael Wagenbach, David C. Anderson, Antony James Mathews, Kiyoshi Nagai
  • Patent number: 5661124
    Abstract: The present invention provides blood substitutes comprised of recombinantly produced mutant hemoglobin having an osmolarity greater than 303 milliosmoles per liter and less than 800 milliosmoles per liter. Such hyperosmolar blood substitute additionally comprises a physiologically acceptable molecule less diffusible than dextrose.
    Type: Grant
    Filed: March 1, 1995
    Date of Patent: August 26, 1997
    Assignee: Somatogen, Inc.
    Inventors: Stephen J. Hoffman, Kiyoshi Nagai
  • Patent number: 5563254
    Abstract: The present invention provides for polynucleotides capable of producing recombinant hemoglobins that have a P.sub.50 of 26-36 torr. This invention makes possible the commercial production of wholly artificial hemoglobin, whether conventional or mutant in form, which can be used as blood substitutes.
    Type: Grant
    Filed: December 20, 1993
    Date of Patent: October 8, 1996
    Assignees: Medical Research Council, Somatogen, Inc.
    Inventors: Stephen J. Hoffman, Kiyoshi Nagai
  • Patent number: 5545727
    Abstract: The alpha subunits of hemoglobin, which in nature are formed as separate polypeptide chains which bind noncovalently to the beta subunits, are here provided in the form of the novel molecule di-alpha globin, a single polypeptide chain defined by connecting the two alpha subunits either directly via peptide bond or indirectly by a flexible amino acid or peptide linker. Di-alpha globin may be combined in vivo or in vitro with beta globin and heme to form hemoglobin. Di-alpha globin is expressed by recombinant DNA techniques. Di-beta globin may be similarly obtained.DNA encoding alpha globin fusion proteins is provided.
    Type: Grant
    Filed: November 8, 1991
    Date of Patent: August 13, 1996
    Assignee: Somatogen, Inc.
    Inventors: Stephen J. Hoffman, Douglas L. Looker, Kiyoshi Nagai
  • Patent number: 5525630
    Abstract: Allosteric hemoglobin modifier compounds are disclosed that clear carbon monoxide hemoglobin from a host animal.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: June 11, 1996
    Assignee: Allos Therapeutics, Inc.
    Inventor: Stephen J. Hoffman
  • Patent number: 5449759
    Abstract: Cysteine substitution mutants of alpha and/or beta globin mutants are produced by recombinant DNA techniques and used in the construction, intracellularly or otherwise, of mutant hemoglobins in which alpha- and beta-globin like subunits are crosslinked by disulfide bonds. Solutions of these mutant hemoglobins are used as blood substitutes.Preferably, these mutant hemoglobins contain further mutations which reduce their affinity for oxygen.Hemoglobins are preferably obtained by recombinant DNA techniques. Both alpha and beta globin chains can now be readily expressed, making possible the commercial production of wholly artificial hemoglobin, whether conventional or mutant in form. Solutions of wholly artificial hemoglobins are also used as blood substitutes. Expression of the alpha globin gene was substantially improved by means of a beta globin gene "header".
    Type: Grant
    Filed: November 29, 1993
    Date of Patent: September 12, 1995
    Assignee: Somatogen, Inc.
    Inventors: Stephen J. Hoffman, Kiyoshi Nagai
  • Patent number: 3996522
    Abstract: A signal-seeking radio receiver is disclosed which has two different types of local oscillator circuits. One type of local oscillator includes two transistors, the emitter of the first connecting to the base of the second and having a capacitor connecting between the emitter of the second and the base of the first. A large number of diode switched crystals can be connected to the base of the first transistor of the local oscillator without introducing an instability in the oscillator circuit. The second type of local oscillator is of the same general design as the first type except that it additionally includes a third transistor connected to the second transistor in a fashion similar to the first transistor. In this second oscillator configuration, the circuitry used to step among the channels also is used to alternately make either the first or third transistor operative in the local oscillator circuit.
    Type: Grant
    Filed: November 17, 1975
    Date of Patent: December 7, 1976
    Assignee: Regency Electronics Inc.
    Inventors: Richard C. Koch, Stephen J. Hoffman